• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
DXB

DIMERIX LIMITED - Announcements

4.81% ! 49.5¢
Market Cap $295.5M  !

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The... Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. It develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The Company is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. More

Announcements



Filters [Clear]
  • Price Sensitive: Yes
DXB Trading HaltPRICE SENSITIVE12/08/21 download Created with Sketch. 363.81KB
DXB DMX-200 COVID-19 Study Opens More Sites in Europe and UKPRICE SENSITIVE02/08/21 download Created with Sketch. 308.9KB
DXB Quarterly Appendix 4C and Activities ReportPRICE SENSITIVE27/07/21 download Created with Sketch. 511.42KB
DXB FDA Confirms Phase 3 Study Design in FSGS Kidney DiseasePRICE SENSITIVE19/07/21 download Created with Sketch. 270.67KB
DXB Dimerix Receives Innovation Passport and ILAP DesignationPRICE SENSITIVE07/06/21 download Created with Sketch. 274.83KB
DXB Dimerix Confirms Phase 3 FSGS Study Design With EMAPRICE SENSITIVE03/06/21 download Created with Sketch. 297.79KB
DXB DMX-200 Remains Eligible for Accelerated ApprovalPRICE SENSITIVE27/05/21 download Created with Sketch. 280.56KB
DXB COVID-19 Study Recruits Multiple Patients in EuropePRICE SENSITIVE23/04/21 download Created with Sketch. 308.13KB
DXB Quarterly Appendix 4C and Activities ReportPRICE SENSITIVE08/04/21 download Created with Sketch. 586.68KB
DXB Major Shareholder Loan for $5 MillionPRICE SENSITIVE30/03/21 download Created with Sketch. 282.98KB
DXB Clinical Study in Patients with COVID-19 ProgressesPRICE SENSITIVE25/03/21 download Created with Sketch. 303.04KB
DXB DMX-200 Competitive Position Further EnhancedPRICE SENSITIVE24/03/21 download Created with Sketch. 256.2KB
DXB CLARITY 2.0 Study Progresses In Patients With COVID-19PRICE SENSITIVE10/03/21 download Created with Sketch. 289.02KB
DXB Appendix 4D and Interim Financial ReportPRICE SENSITIVE22/02/21 download Created with Sketch. 956.04KB
DXB Dimerix Plans for Next Study in Diabetic Kidney DiseasePRICE SENSITIVE28/01/21 download Created with Sketch. 406.67KB
DXB Quarterly Appendix 4C and Activities ReportPRICE SENSITIVE22/01/21 download Created with Sketch. 569.96KB
DXB Second Study to Include DMX-200 in COVID-19 PatientsPRICE SENSITIVE30/11/20 download Created with Sketch. 236.94KB
DXB ARDS in COVID-19 Patients Protocol PublishedPRICE SENSITIVE09/11/20 download Created with Sketch. 234.24KB
DXB Positive Additional Data to Support DMX-200 DevelopmentPRICE SENSITIVE27/10/20 download Created with Sketch. 3.7MB
DXB Quarterly Appendix 4C and Activities ReportPRICE SENSITIVE23/10/20 download Created with Sketch. 662.36KB
DXB Receipt of R&D Tax IncentivePRICE SENSITIVE21/10/20 download Created with Sketch. 282.29KB
DXB DMX-700 Data Demonstrates Effect on Key COPD ReceptorsPRICE SENSITIVE07/10/20 download Created with Sketch. 335.48KB
DXB Positive Top-Line Results in DKD Phase 2 Clinical StudyPRICE SENSITIVE14/09/20 download Created with Sketch. 307.24KB
DXB Trading HaltPRICE SENSITIVE10/09/20 download Created with Sketch. 363.42KB
DXB Dimerix Awarded $1 Million MRFF FundingPRICE SENSITIVE03/09/20 download Created with Sketch. 354.09KB
DXB Preliminary Final ReportPRICE SENSITIVE27/08/20 download Created with Sketch. 126.66KB
DXB Positive Top-Line Results in FSGS Phase 2a Clinical StudyPRICE SENSITIVE29/07/20 download Created with Sketch. 279.06KB
DXB Trading HaltPRICE SENSITIVE27/07/20 download Created with Sketch. 364.82KB
DXB Last Patient Completes Dosing in DKD Phase 2 Clinical StudyPRICE SENSITIVE24/07/20 download Created with Sketch. 245.43KB
DXB Quarterly Appendix 4C and Activities ReportPRICE SENSITIVE14/07/20 download Created with Sketch. 552.22KB
DXB Dimerix Completes $5.8m PlacementPRICE SENSITIVE22/06/20 download Created with Sketch. 258.28KB
DXB Trading HaltPRICE SENSITIVE18/06/20 download Created with Sketch. 553.4KB
DXB Last Patient Completes Dosing in FSGS Phase 2 Clinical StudyPRICE SENSITIVE17/06/20 download Created with Sketch. 261.83KB
DXB Global REMAP-CAP Platform Trial Protocol To Include DMX-200PRICE SENSITIVE04/06/20 download Created with Sketch. 287.37KB
DXB Trading HaltPRICE SENSITIVE02/06/20 download Created with Sketch. 363.65KB
DXB Quarterly Appendix 4C and Activities ReportPRICE SENSITIVE21/04/20 download Created with Sketch. 447.79KB
DXB R&D Tax Incentive FacilityPRICE SENSITIVE03/04/20 download Created with Sketch. 263.77KB
DXB DMX-200 Treatment Continued Under TGA Special Access SchemePRICE SENSITIVE03/03/20 download Created with Sketch. 291.19KB
DXB Half Yearly Report and AccountsPRICE SENSITIVE19/02/20 download Created with Sketch. 1.19MB
DXB Quarterly Commentary & Appendix 4CPRICE SENSITIVE21/01/20 download Created with Sketch. 512.51KB
DXB DMX-200 Clinical Trial UpdatePRICE SENSITIVE07/01/20 download Created with Sketch. 274.26KB
DXB Dimerix Completes $2.5m PlacementPRICE SENSITIVE03/12/19 download Created with Sketch. 281.55KB
DXB Trading HaltPRICE SENSITIVE29/11/19 download Created with Sketch. 556.96KB
DXB Dimerix Holds Pre-IND Meeting on DMX-200 With FDAPRICE SENSITIVE25/11/19 download Created with Sketch. 227.79KB
DXB Quarterly Commentary & Appendix 4CPRICE SENSITIVE25/10/19 download Created with Sketch. 565.91KB
DXB New Drug Pipeline Candidate DMX-700 & Company UpdatePRICE SENSITIVE10/10/19 download Created with Sketch. 3.08MB
DXB Receipt of R&D Tax IncentivePRICE SENSITIVE08/10/19 download Created with Sketch. 225.43KB
DXB DMX-200 Phase 2 Clinical Study in DKD Completes RecruitmentPRICE SENSITIVE26/09/19 download Created with Sketch. 180.46KB
DXB Preliminary Final ReportPRICE SENSITIVE29/08/19 download Created with Sketch. 95.58KB
DXB Quarterly Commentary & Appendix 4CPRICE SENSITIVE16/07/19 download Created with Sketch. 350.91KB
DXB DMX-200 Phase 2 Clinical Trial in FSGS Fully RecruitedPRICE SENSITIVE10/07/19 download Created with Sketch. 231.92KB
DXB DMX-200 Clinical UpdatePRICE SENSITIVE26/06/19 download Created with Sketch. 280.1KB
DXB Dimerix Signs Licence Agreement for Receptor-HIT TechnologyPRICE SENSITIVE24/06/19 download Created with Sketch. 195.39KB
DXB DMX-200 Manufacturing UpdatePRICE SENSITIVE27/05/19 download Created with Sketch. 256.75KB
DXB Appendix 4C - quarterlyPRICE SENSITIVE26/04/19 download Created with Sketch. 146.02KB
DXB Half Yearly Report and AccountsPRICE SENSITIVE26/02/19 download Created with Sketch. 1.22MB
DXB Appendix 4C and Quarterly HighlightsPRICE SENSITIVE31/01/19 download Created with Sketch. 311.52KB
DXB Dimerix Receives R&D Tax Cash Rebate Totalling $1.07mPRICE SENSITIVE20/12/18 download Created with Sketch. 124.97KB
DXB 1st Patient Dosed in DMX-200 Clinical Trial for FSGSPRICE SENSITIVE22/11/18 download Created with Sketch. 133.95KB
DXB DXB Receives Orphan Drug Designation in EUPRICE SENSITIVE21/11/18 download Created with Sketch. 186.18KB
DXB FIRST PATIENT DOSED IN DMX-200 CLINICAL TRIALPRICE SENSITIVE19/11/18 download Created with Sketch. 132.96KB
DXB Appendix 4C - quarterlyPRICE SENSITIVE29/10/18 download Created with Sketch. 148.78KB
DXB Preliminary Final ReportPRICE SENSITIVE30/08/18 download Created with Sketch. 151.46KB
DXB EXECUTIVE TEAM BOLSTERED THROUGH CEO & MD APPOINTMENTPRICE SENSITIVE27/08/18 download Created with Sketch. 155.28KB
DXB Quarterly Review & Appendix 4CPRICE SENSITIVE31/07/18 download Created with Sketch. 380.79KB
DXB Ethics Approval Received Appendix 3B and S.708A NoticePRICE SENSITIVE18/07/18 download Created with Sketch. 732.36KB
DXB Further US patent allowed for DMX-200PRICE SENSITIVE02/07/18 download Created with Sketch. 66.48KB
DXB Dual Phase 2 trials launched for CKDPRICE SENSITIVE15/05/18 download Created with Sketch. 100.67KB
DXB Quarterly Review & Appendix 4CPRICE SENSITIVE27/04/18 download Created with Sketch. 374.85KB
DXB Westar Capital Retained as Corporate AdvisorsPRICE SENSITIVE12/04/18 download Created with Sketch. 125.41KB
DXB CMO Appointment and Clinical Trials UpdatePRICE SENSITIVE27/03/18 download Created with Sketch. 183.95KB
DXB Half Year Report and Financial StatementsPRICE SENSITIVE26/02/18 download Created with Sketch. 1.7MB
DXB Oversubscribed Placement to Raise a Further $4.5mPRICE SENSITIVE21/02/18 download Created with Sketch. 157.84KB
DXB Trading HaltPRICE SENSITIVE19/02/18 download Created with Sketch. 181.58KB
DXB Quarterly Review and Appendix 4CPRICE SENSITIVE29/01/18 download Created with Sketch. 677.71KB
DXB Results of Entitlement OfferPRICE SENSITIVE24/01/18 download Created with Sketch. 124.38KB
DXB DMX-200 Dosage Optimisation Study Successfully CompletedPRICE SENSITIVE08/01/18 download Created with Sketch. 340.34KB
DXB Proteomics partnership to improve treatment of CKDPRICE SENSITIVE14/12/17 download Created with Sketch. 134.42KB
DXB Reinstatement to Official QuotationPRICE SENSITIVE06/12/17 download Created with Sketch. 87.78KB
DXB Entitlement Offer BookletPRICE SENSITIVE06/12/17 download Created with Sketch. 723.42KB
DXB Entitlement Offer to raise $5.5 millionPRICE SENSITIVE06/12/17 download Created with Sketch. 51.89KB
DXB Suspension from Official QuotationPRICE SENSITIVE05/12/17 download Created with Sketch. 685.45KB
DXB Trading HaltPRICE SENSITIVE01/12/17 download Created with Sketch. 465.66KB
DXB Dimerix Phase 2a Subgroup Analysis ResultsPRICE SENSITIVE02/11/17 download Created with Sketch. 485.66KB
DXB Quarterly Review and Appendix 4CPRICE SENSITIVE31/10/17 download Created with Sketch. 740.98KB
DXB Ethics Committee Approval for Pharmacokinetic TrialPRICE SENSITIVE24/10/17 download Created with Sketch. 337.67KB
DXB Dimerix Receives $545k R&D Tax RefundPRICE SENSITIVE17/10/17 download Created with Sketch. 491.55KB
DXB Notice of Annual General Meeting/Proxy FormPRICE SENSITIVE13/09/17 download Created with Sketch. 1.37MB
DXB DMX-200 tablet manufacture and human study timelinePRICE SENSITIVE05/09/17 download Created with Sketch. 268.97KB
DXB Preliminary Final ReportPRICE SENSITIVE30/08/17 download Created with Sketch. 395.33KB
DXB Appendix 4C - quarterlyPRICE SENSITIVE31/07/17 download Created with Sketch. 416.41KB
DXB Positive Results from Phase 2a Trial of DMX-200PRICE SENSITIVE12/07/17 download Created with Sketch. 454.66KB
DXB Trading HaltPRICE SENSITIVE11/07/17 download Created with Sketch. 641.41KB
DXB Research Validates Relevance of DMX Receptor-HIT TechnologyPRICE SENSITIVE13/06/17 download Created with Sketch. 298.86KB
DXB Appendix 4C - quarterlyPRICE SENSITIVE28/04/17 download Created with Sketch. 232.69KB
DXB Investor UpdatePRICE SENSITIVE11/04/17 download Created with Sketch. 1.49MB
DXB Receipt of $420k Research & Development Tax RefundPRICE SENSITIVE21/03/17 download Created with Sketch. 334.02KB
DXB Half Yearly Report and AccountsPRICE SENSITIVE21/02/17 download Created with Sketch. 2.28MB
DXB Corporate PresentationPRICE SENSITIVE14/02/17 download Created with Sketch. 7.02MB
DXB Key Patent Allowed in JapanPRICE SENSITIVE31/01/17 download Created with Sketch. 332.27KB
DXB Trading Halt
12/08/21PRICE SENSITIVE download Created with Sketch. 363.81KB
DXB DMX-200 COVID-19 Study Opens More Sites in Europe and UK
02/08/21PRICE SENSITIVE download Created with Sketch. 308.9KB
DXB Quarterly Appendix 4C and Activities Report
27/07/21PRICE SENSITIVE download Created with Sketch. 511.42KB
DXB FDA Confirms Phase 3 Study Design in FSGS Kidney Disease
19/07/21PRICE SENSITIVE download Created with Sketch. 270.67KB
DXB Dimerix Receives Innovation Passport and ILAP Designation
07/06/21PRICE SENSITIVE download Created with Sketch. 274.83KB
DXB Dimerix Confirms Phase 3 FSGS Study Design With EMA
03/06/21PRICE SENSITIVE download Created with Sketch. 297.79KB
DXB DMX-200 Remains Eligible for Accelerated Approval
27/05/21PRICE SENSITIVE download Created with Sketch. 280.56KB
DXB COVID-19 Study Recruits Multiple Patients in Europe
23/04/21PRICE SENSITIVE download Created with Sketch. 308.13KB
DXB Quarterly Appendix 4C and Activities Report
08/04/21PRICE SENSITIVE download Created with Sketch. 586.68KB
DXB Major Shareholder Loan for $5 Million
30/03/21PRICE SENSITIVE download Created with Sketch. 282.98KB
DXB Clinical Study in Patients with COVID-19 Progresses
25/03/21PRICE SENSITIVE download Created with Sketch. 303.04KB
DXB DMX-200 Competitive Position Further Enhanced
24/03/21PRICE SENSITIVE download Created with Sketch. 256.2KB
DXB CLARITY 2.0 Study Progresses In Patients With COVID-19
10/03/21PRICE SENSITIVE download Created with Sketch. 289.02KB
DXB Appendix 4D and Interim Financial Report
22/02/21PRICE SENSITIVE download Created with Sketch. 956.04KB
DXB Dimerix Plans for Next Study in Diabetic Kidney Disease
28/01/21PRICE SENSITIVE download Created with Sketch. 406.67KB
DXB Quarterly Appendix 4C and Activities Report
22/01/21PRICE SENSITIVE download Created with Sketch. 569.96KB
DXB Second Study to Include DMX-200 in COVID-19 Patients
30/11/20PRICE SENSITIVE download Created with Sketch. 236.94KB
DXB ARDS in COVID-19 Patients Protocol Published
09/11/20PRICE SENSITIVE download Created with Sketch. 234.24KB
DXB Positive Additional Data to Support DMX-200 Development
27/10/20PRICE SENSITIVE download Created with Sketch. 3.7MB
DXB Quarterly Appendix 4C and Activities Report
23/10/20PRICE SENSITIVE download Created with Sketch. 662.36KB
DXB Receipt of R&D Tax Incentive
21/10/20PRICE SENSITIVE download Created with Sketch. 282.29KB
DXB DMX-700 Data Demonstrates Effect on Key COPD Receptors
07/10/20PRICE SENSITIVE download Created with Sketch. 335.48KB
DXB Positive Top-Line Results in DKD Phase 2 Clinical Study
14/09/20PRICE SENSITIVE download Created with Sketch. 307.24KB
DXB Trading Halt
10/09/20PRICE SENSITIVE download Created with Sketch. 363.42KB
DXB Dimerix Awarded $1 Million MRFF Funding
03/09/20PRICE SENSITIVE download Created with Sketch. 354.09KB
DXB Preliminary Final Report
27/08/20PRICE SENSITIVE download Created with Sketch. 126.66KB
DXB Positive Top-Line Results in FSGS Phase 2a Clinical Study
29/07/20PRICE SENSITIVE download Created with Sketch. 279.06KB
DXB Trading Halt
27/07/20PRICE SENSITIVE download Created with Sketch. 364.82KB
DXB Last Patient Completes Dosing in DKD Phase 2 Clinical Study
24/07/20PRICE SENSITIVE download Created with Sketch. 245.43KB
DXB Quarterly Appendix 4C and Activities Report
14/07/20PRICE SENSITIVE download Created with Sketch. 552.22KB
DXB Dimerix Completes $5.8m Placement
22/06/20PRICE SENSITIVE download Created with Sketch. 258.28KB
DXB Trading Halt
18/06/20PRICE SENSITIVE download Created with Sketch. 553.4KB
DXB Last Patient Completes Dosing in FSGS Phase 2 Clinical Study
17/06/20PRICE SENSITIVE download Created with Sketch. 261.83KB
DXB Global REMAP-CAP Platform Trial Protocol To Include DMX-200
04/06/20PRICE SENSITIVE download Created with Sketch. 287.37KB
DXB Trading Halt
02/06/20PRICE SENSITIVE download Created with Sketch. 363.65KB
DXB Quarterly Appendix 4C and Activities Report
21/04/20PRICE SENSITIVE download Created with Sketch. 447.79KB
DXB R&D Tax Incentive Facility
03/04/20PRICE SENSITIVE download Created with Sketch. 263.77KB
DXB DMX-200 Treatment Continued Under TGA Special Access Scheme
03/03/20PRICE SENSITIVE download Created with Sketch. 291.19KB
DXB Half Yearly Report and Accounts
19/02/20PRICE SENSITIVE download Created with Sketch. 1.19MB
DXB Quarterly Commentary & Appendix 4C
21/01/20PRICE SENSITIVE download Created with Sketch. 512.51KB
DXB DMX-200 Clinical Trial Update
07/01/20PRICE SENSITIVE download Created with Sketch. 274.26KB
DXB Dimerix Completes $2.5m Placement
03/12/19PRICE SENSITIVE download Created with Sketch. 281.55KB
DXB Trading Halt
29/11/19PRICE SENSITIVE download Created with Sketch. 556.96KB
DXB Dimerix Holds Pre-IND Meeting on DMX-200 With FDA
25/11/19PRICE SENSITIVE download Created with Sketch. 227.79KB
DXB Quarterly Commentary & Appendix 4C
25/10/19PRICE SENSITIVE download Created with Sketch. 565.91KB
DXB New Drug Pipeline Candidate DMX-700 & Company Update
10/10/19PRICE SENSITIVE download Created with Sketch. 3.08MB
DXB Receipt of R&D Tax Incentive
08/10/19PRICE SENSITIVE download Created with Sketch. 225.43KB
DXB DMX-200 Phase 2 Clinical Study in DKD Completes Recruitment
26/09/19PRICE SENSITIVE download Created with Sketch. 180.46KB
DXB Preliminary Final Report
29/08/19PRICE SENSITIVE download Created with Sketch. 95.58KB
DXB Quarterly Commentary & Appendix 4C
16/07/19PRICE SENSITIVE download Created with Sketch. 350.91KB
DXB DMX-200 Phase 2 Clinical Trial in FSGS Fully Recruited
10/07/19PRICE SENSITIVE download Created with Sketch. 231.92KB
DXB DMX-200 Clinical Update
26/06/19PRICE SENSITIVE download Created with Sketch. 280.1KB
DXB Dimerix Signs Licence Agreement for Receptor-HIT Technology
24/06/19PRICE SENSITIVE download Created with Sketch. 195.39KB
DXB DMX-200 Manufacturing Update
27/05/19PRICE SENSITIVE download Created with Sketch. 256.75KB
DXB Appendix 4C - quarterly
26/04/19PRICE SENSITIVE download Created with Sketch. 146.02KB
DXB Half Yearly Report and Accounts
26/02/19PRICE SENSITIVE download Created with Sketch. 1.22MB
DXB Appendix 4C and Quarterly Highlights
31/01/19PRICE SENSITIVE download Created with Sketch. 311.52KB
DXB Dimerix Receives R&D Tax Cash Rebate Totalling $1.07m
20/12/18PRICE SENSITIVE download Created with Sketch. 124.97KB
DXB 1st Patient Dosed in DMX-200 Clinical Trial for FSGS
22/11/18PRICE SENSITIVE download Created with Sketch. 133.95KB
DXB DXB Receives Orphan Drug Designation in EU
21/11/18PRICE SENSITIVE download Created with Sketch. 186.18KB
DXB FIRST PATIENT DOSED IN DMX-200 CLINICAL TRIAL
19/11/18PRICE SENSITIVE download Created with Sketch. 132.96KB
DXB Appendix 4C - quarterly
29/10/18PRICE SENSITIVE download Created with Sketch. 148.78KB
DXB Preliminary Final Report
30/08/18PRICE SENSITIVE download Created with Sketch. 151.46KB
DXB EXECUTIVE TEAM BOLSTERED THROUGH CEO & MD APPOINTMENT
27/08/18PRICE SENSITIVE download Created with Sketch. 155.28KB
DXB Quarterly Review & Appendix 4C
31/07/18PRICE SENSITIVE download Created with Sketch. 380.79KB
DXB Ethics Approval Received Appendix 3B and S.708A Notice
18/07/18PRICE SENSITIVE download Created with Sketch. 732.36KB
DXB Further US patent allowed for DMX-200
02/07/18PRICE SENSITIVE download Created with Sketch. 66.48KB
DXB Dual Phase 2 trials launched for CKD
15/05/18PRICE SENSITIVE download Created with Sketch. 100.67KB
DXB Quarterly Review & Appendix 4C
27/04/18PRICE SENSITIVE download Created with Sketch. 374.85KB
DXB Westar Capital Retained as Corporate Advisors
12/04/18PRICE SENSITIVE download Created with Sketch. 125.41KB
DXB CMO Appointment and Clinical Trials Update
27/03/18PRICE SENSITIVE download Created with Sketch. 183.95KB
DXB Half Year Report and Financial Statements
26/02/18PRICE SENSITIVE download Created with Sketch. 1.7MB
DXB Oversubscribed Placement to Raise a Further $4.5m
21/02/18PRICE SENSITIVE download Created with Sketch. 157.84KB
DXB Trading Halt
19/02/18PRICE SENSITIVE download Created with Sketch. 181.58KB
DXB Quarterly Review and Appendix 4C
29/01/18PRICE SENSITIVE download Created with Sketch. 677.71KB
DXB Results of Entitlement Offer
24/01/18PRICE SENSITIVE download Created with Sketch. 124.38KB
DXB DMX-200 Dosage Optimisation Study Successfully Completed
08/01/18PRICE SENSITIVE download Created with Sketch. 340.34KB
DXB Proteomics partnership to improve treatment of CKD
14/12/17PRICE SENSITIVE download Created with Sketch. 134.42KB
DXB Reinstatement to Official Quotation
06/12/17PRICE SENSITIVE download Created with Sketch. 87.78KB
DXB Entitlement Offer Booklet
06/12/17PRICE SENSITIVE download Created with Sketch. 723.42KB
DXB Entitlement Offer to raise $5.5 million
06/12/17PRICE SENSITIVE download Created with Sketch. 51.89KB
DXB Suspension from Official Quotation
05/12/17PRICE SENSITIVE download Created with Sketch. 685.45KB
DXB Trading Halt
01/12/17PRICE SENSITIVE download Created with Sketch. 465.66KB
DXB Dimerix Phase 2a Subgroup Analysis Results
02/11/17PRICE SENSITIVE download Created with Sketch. 485.66KB
DXB Quarterly Review and Appendix 4C
31/10/17PRICE SENSITIVE download Created with Sketch. 740.98KB
DXB Ethics Committee Approval for Pharmacokinetic Trial
24/10/17PRICE SENSITIVE download Created with Sketch. 337.67KB
DXB Dimerix Receives $545k R&D Tax Refund
17/10/17PRICE SENSITIVE download Created with Sketch. 491.55KB
DXB Notice of Annual General Meeting/Proxy Form
13/09/17PRICE SENSITIVE download Created with Sketch. 1.37MB
DXB DMX-200 tablet manufacture and human study timeline
05/09/17PRICE SENSITIVE download Created with Sketch. 268.97KB
DXB Preliminary Final Report
30/08/17PRICE SENSITIVE download Created with Sketch. 395.33KB
DXB Appendix 4C - quarterly
31/07/17PRICE SENSITIVE download Created with Sketch. 416.41KB
DXB Positive Results from Phase 2a Trial of DMX-200
12/07/17PRICE SENSITIVE download Created with Sketch. 454.66KB
DXB Trading Halt
11/07/17PRICE SENSITIVE download Created with Sketch. 641.41KB
DXB Research Validates Relevance of DMX Receptor-HIT Technology
13/06/17PRICE SENSITIVE download Created with Sketch. 298.86KB
DXB Appendix 4C - quarterly
28/04/17PRICE SENSITIVE download Created with Sketch. 232.69KB
DXB Investor Update
11/04/17PRICE SENSITIVE download Created with Sketch. 1.49MB
DXB Receipt of $420k Research & Development Tax Refund
21/03/17PRICE SENSITIVE download Created with Sketch. 334.02KB
DXB Half Yearly Report and Accounts
21/02/17PRICE SENSITIVE download Created with Sketch. 2.28MB
DXB Corporate Presentation
14/02/17PRICE SENSITIVE download Created with Sketch. 7.02MB
DXB Key Patent Allowed in Japan
31/01/17PRICE SENSITIVE download Created with Sketch. 332.27KB
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
49.5¢
Change
-0.025(4.81%)
Mkt cap ! $295.5M
Open High Low Value Volume
52.0¢ 52.3¢ 49.0¢ $459.4K 918.9K

Buyers (Bids)

No. Vol. Price($)
7 59571 49.0¢
 

Sellers (Offers)

Price($) Vol. No.
49.5¢ 51445 7
View Market Depth
Last trade - 14.25pm 11/08/2025 (20 minute delay) ?
Last
49.0¢
  Change
-0.025 ( 4.85 %)
Open High Low Volume
52.5¢ 52.5¢ 49.0¢ 413140
Last updated 14.49pm 11/08/2025 ?
DXB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.